v3.26.3
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Segment Reporting [Line Items]          
Assets $ 10,783,100   $ 10,783,100   $ 10,576,500
Interest expense (12,300) $ (12,300) (36,700) $ (36,900)  
Foreign Currency Transaction Gain (Loss), before Tax 2,100 2,900 4,700 4,500  
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 538,700 (431,100) 391,000 66,300  
Marketable Securities, Unrealized Gain (Loss) 588,200 (495,300) 308,000 (129,100)  
Other Nonoperating Income (Expense) 10,400 8,300 58,000 61,700  
Other Nonoperating (Income) 500 1,000 2,000 2,200  
Net sales 656,400 653,000 1,899,500 1,890,000  
Cost of goods sold 327,800 309,600 915,700 895,300  
Gross profit 328,600 343,400 983,800 994,700  
Selling, general and administrative expense (257,100) (206,800) (681,500) (623,300)  
Research and Development Expense (71,400) (71,300) (195,500) (205,300)  
Impairment of purchased intangibles 49,800 0 49,800 0  
Life Science          
Segment Reporting [Line Items]          
Net sales 254,600 261,800 735,100 753,200  
Cost of goods sold 122,400 115,900 331,800 330,600  
Depreciation, Depletion and Amortization 17,800 20,600 54,300 55,400  
Gross profit 132,200 145,900 403,300 422,600  
Clinical Diagnostics          
Segment Reporting [Line Items]          
Net sales 401,800 391,200 1,164,400 1,136,800  
Cost of goods sold 205,400 193,700 583,900 564,700  
Depreciation, Depletion and Amortization 23,400 23,600 68,900 67,500  
Gross profit 196,400 197,500 580,500 572,100  
Operating Segments          
Segment Reporting [Line Items]          
Gross profit 328,600 343,400 983,800 994,700  
Selling, general and administrative expense (257,100) (206,800) (681,500) (623,300)  
Research and Development Expense (71,400) (71,300) (195,500) (205,300)  
Impairment of purchased intangibles 49,800 0 49,800 0  
Operating Segments | Life Science          
Segment Reporting [Line Items]          
Assets 301,300 310,900 301,300 310,900  
Operating Segments | Clinical Diagnostics          
Segment Reporting [Line Items]          
Assets 482,600 472,300 482,600 472,300  
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment          
Segment Reporting [Line Items]          
Foreign Currency Transaction Gain (Loss), before Tax 2,100 2,900 4,700 4,500  
Marketable Securities, Unrealized Gain (Loss) 588,200 (495,300) 308,000 (129,100)  
Other Nonoperating Income (Expense) 10,400 8,300 58,000 61,700  
Location, Statement of Income, Balance [Axis]: us-gaap:InterestExpense | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment          
Segment Reporting [Line Items]          
Interest expense $ (12,300) $ (12,300) $ (36,700) $ (36,900)